These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 31558784)

  • 41. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations.
    Quiros RM; Ding HG; Gattuso P; Prinz RA; Xu X
    Cancer; 2005 Jun; 103(11):2261-8. PubMed ID: 15880523
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Genotyping of an Italian papillary thyroid carcinoma cohort revealed high prevalence of BRAF mutations, absence of RAS mutations and allowed the detection of a new mutation of BRAF oncoprotein (BRAF(V599lns)).
    Carta C; Moretti S; Passeri L; Barbi F; Avenia N; Cavaliere A; Monacelli M; Macchiarulo A; Santeusanio F; Tartaglia M; Puxeddu E
    Clin Endocrinol (Oxf); 2006 Jan; 64(1):105-9. PubMed ID: 16402937
    [TBL] [Abstract][Full Text] [Related]  

  • 43. RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.
    Hamatani K; Eguchi H; Ito R; Mukai M; Takahashi K; Taga M; Imai K; Cologne J; Soda M; Arihiro K; Fujihara M; Abe K; Hayashi T; Nakashima M; Sekine I; Yasui W; Hayashi Y; Nakachi K
    Cancer Res; 2008 Sep; 68(17):7176-82. PubMed ID: 18757433
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular Profiling of Salivary Gland Intraductal Carcinoma Revealed a Subset of Tumors Harboring NCOA4-RET and Novel TRIM27-RET Fusions: A Report of 17 cases.
    Skálová A; Vanecek T; Uro-Coste E; Bishop JA; Weinreb I; Thompson LDR; de Sanctis S; Schiavo-Lena M; Laco J; Badoual C; Santana Conceiçao T; Ptáková N; Baněčkova M; Miesbauerová M; Michal M
    Am J Surg Pathol; 2018 Nov; 42(11):1445-1455. PubMed ID: 30045065
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Acinar cell carcinomas of the pancreas: a molecular analysis in a series of 57 cases.
    Bergmann F; Aulmann S; Sipos B; Kloor M; von Heydebreck A; Schweipert J; Harjung A; Mayer P; Hartwig W; Moldenhauer G; Capper D; Dyckhoff G; Freier K; Herpel E; Schleider A; Schirmacher P; Mechtersheimer G; Klöppel G; Bläker H
    Virchows Arch; 2014 Dec; 465(6):661-72. PubMed ID: 25298229
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
    Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
    World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Gastric mixed neuroendocrine-non-neuroendocrine neoplasm (MiNEN) with pancreatic acinar differentiation: a case report.
    Fujita Y; Uesugi N; Sugimoto R; Eizuka M; Matsumoto T; Sugai T
    Diagn Pathol; 2019 May; 14(1):38. PubMed ID: 31077220
    [TBL] [Abstract][Full Text] [Related]  

  • 48. From genotype to phenotype: Are there imaging characteristics associated with lung adenocarcinomas harboring RET and ROS1 rearrangements?
    Plodkowski AJ; Drilon A; Halpenny DF; O'Driscoll D; Blair D; Litvak AM; Zheng J; Moskowitz CS; Ginsberg MS
    Lung Cancer; 2015 Nov; 90(2):321-5. PubMed ID: 26424208
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Relevance of BRAF(V600E) mutation testing versus RAS point mutations and RET/PTC rearrangements evaluation in the diagnosis of thyroid cancer.
    Rossi M; Buratto M; Tagliati F; Rossi R; Lupo S; Trasforini G; Lanza G; Franceschetti P; Bruni S; Degli Uberti E; Zatelli MC
    Thyroid; 2015 Feb; 25(2):221-8. PubMed ID: 25333496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. RET rearrangements and BRAF mutation in undifferentiated thyroid carcinomas having papillary carcinoma components.
    Mochizuki K; Kondo T; Nakazawa T; Iwashina M; Kawasaki T; Nakamura N; Yamane T; Murata S; Ito K; Kameyama K; Kobayashi M; Katoh R
    Histopathology; 2010 Sep; 57(3):444-50. PubMed ID: 20840674
    [TBL] [Abstract][Full Text] [Related]  

  • 51. RET/PTC and PAX8/PPARγ chromosomal rearrangements in post-Chernobyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics.
    Leeman-Neill RJ; Brenner AV; Little MP; Bogdanova TI; Hatch M; Zurnadzy LY; Mabuchi K; Tronko MD; Nikiforov YE
    Cancer; 2013 May; 119(10):1792-9. PubMed ID: 23436219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Nonductal Pancreatic Cancers.
    Jun SY; Hong SM
    Surg Pathol Clin; 2016 Dec; 9(4):581-593. PubMed ID: 27926361
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The Frequency and Clinical Implication of ROS1 and RET Rearrangements in Resected Stage IIIA-N2 Non-Small Cell Lung Cancer Patients.
    Fu S; Liang Y; Lin YB; Wang F; Huang MY; Zhang ZC; Wang J; Cen WJ; Shao JY
    PLoS One; 2015; 10(4):e0124354. PubMed ID: 25905642
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low prevalence of RET rearrangements (RET/PTC1, RET/PTC2, RET/PTC3, and ELKS-RET) in sporadic papillary thyroid carcinomas in Taiwan Chinese.
    Liu RT; Chou FF; Wang CH; Lin CL; Chao FP; Chung JC; Huang CC; Wang PW; Cheng JT
    Thyroid; 2005 Apr; 15(4):326-35. PubMed ID: 15876154
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
    Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
    Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pan-tropomyosin receptor kinase immunoreactivity, ETV6-NTRK3 fusion subtypes, and RET rearrangement in salivary secretory carcinoma.
    Yamamoto H; Nozaki Y; Sugii A; Taguchi K; Hongo T; Jiromaru R; Sato M; Nakano T; Hashimoto K; Fujiwara M; Oda Y
    Hum Pathol; 2021 Mar; 109():37-44. PubMed ID: 33301751
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Comparison of Morphologic and Molecular Features of BRAF, ALK, and NTRK1 Fusion Spitzoid Neoplasms.
    Amin SM; Haugh AM; Lee CY; Zhang B; Bubley JA; Merkel EA; Verzì AE; Gerami P
    Am J Surg Pathol; 2017 Apr; 41(4):491-498. PubMed ID: 27776007
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinicopathological characteristics and survival of ALK, ROS1 and RET rearrangements in non-adenocarcinoma non-small cell lung cancer patients.
    Song Z; Yu X; Zhang Y
    Cancer Biol Ther; 2017 Nov; 18(11):883-887. PubMed ID: 27635639
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
    Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
    Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Comprehensive analysis of
    Zhou C; Li M; Guo Z; Li K; Zhai X; Xie Y; Yang X; Wu Y; Xiao W; Xu W
    J Genet; 2020; 99():. PubMed ID: 33168793
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.